Nkarta Inc
NKTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$202.47M
Close$
$-0.50
118% downside
Current Fair Value
118% downsideOvervalued by 118% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $202.47 Million |
|---|---|
| Enterprise Value | $251.05 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.41 |
| Beta | 0.98 |
| Outstanding Shares | 74,494,855 |
Return
| Return on Equity | -47.36% |
|---|---|
| Return on Assets | -34.75% |
| Return on Invested Capital | -39.45% |
Valuation & Multiples
| P/E Ratio | -1.8 |
|---|---|
| PEG | -2.38 |
| Price to Sales | - |
| Price to Book Ratio | 0.92 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.03 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1703▼ 36.76% |
|---|---|
| Total Calls | 101,000▲ 47.23% |
| Total Puts | 17,200▼ 53.39% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 79.84%▲ 2.14% |
|---|---|
| Total Invested | $168.88M▲ 38.84% |
| Investors Holding | 141▲ 11.00% |
ESG Score
No data
About Nkarta Inc
95 employeesNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off the shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell en...